Leerink Partnrs Analysts Raise Earnings Estimates for XENE

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Stock analysts at Leerink Partnrs raised their Q1 2025 EPS estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of ($0.91) per share for the quarter, up from their prior forecast of ($0.97). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($1.14) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.50) EPS, FY2026 earnings at ($4.60) EPS, FY2027 earnings at ($3.85) EPS, FY2028 earnings at ($3.05) EPS and FY2029 earnings at $0.25 EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.05.

A number of other equities analysts also recently issued reports on XENE. StockNews.com downgraded Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Royal Bank of Canada restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Finally, The Goldman Sachs Group lowered their price target on Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating for the company in a research report on Thursday. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $56.78.

Xenon Pharmaceuticals Stock Up 4.0 %

Shares of Xenon Pharmaceuticals stock opened at $35.14 on Wednesday. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $46.00. The firm’s 50 day moving average price is $35.08 and its 200-day moving average price is $38.84. The company has a market cap of $2.69 billion, a P/E ratio of -12.46 and a beta of 1.21.

Institutional Trading of Xenon Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Prudential Financial Inc. lifted its position in shares of Xenon Pharmaceuticals by 177.7% during the 4th quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company’s stock valued at $1,529,000 after buying an additional 24,956 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Barclays PLC grew its position in shares of Xenon Pharmaceuticals by 1,275.5% in the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $590,000 after purchasing an additional 13,903 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Xenon Pharmaceuticals by 12.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company’s stock worth $9,350,000 after purchasing an additional 26,235 shares in the last quarter. Finally, State Street Corp raised its position in shares of Xenon Pharmaceuticals by 13.2% during the 3rd quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company’s stock worth $11,004,000 after purchasing an additional 32,701 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 22,468 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at $1,258,340.40. This represents a 41.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.52% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.